Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 17/20 | 0.56 |
| ▸ | ABHD6 | Q9BV23 | 8/20 | 0.56 |
| ▸ | PLA2G7 | Q13093 | 6/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19974356 | 0.88 | MGLL (0.61) | MGLLABHD6PLA2G7 | |
| SCHEMBL21082967 | 0.82 | MGLL (0.63) | MGLLABHD6PLA2G7CYP2D6 | |
| SCHEMBL28303847 | 0.80 | DDR1 (0.40) | — | |
| SCHEMBL19975519 | 0.80 | CYP2D6 (0.51) | MGLLCYP2D6 | |
| SCHEMBL18064816 | 0.80 | MGLL (0.74) | MGLLABHD6PLA2G7CYP2D6 | |
| SCHEMBL29532670 | 0.77 | MGLL (0.61) | MGLL | |
| SCHEMBL20769556 | 0.77 | MGLL (0.61) | MGLL | |
| SCHEMBL19974336 | 0.77 | MGLL (0.67) | MGLLABHD6PLA2G7CYP2D6 | |
| SCHEMBL19974335 | 0.76 | MGLL (0.62) | MGLLABHD6PLA2G7CYP2D6 | |
| SCHEMBL19974348 | 0.76 | STS (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515897-B1 | PIPERAZINE CARBAMATES AS MODULATORS OF MAGL AND/OR ABHD6 AND THEIR USE | H LUNDBECK AS (DK) | 2021-08-18 | — | — | EP | disclosed |
| US-10899737-B2 | Piperazine carbamates and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3515897-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20190202801-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2019-07-04 | — | — | US | disclosed |
| WO-2018053447-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899737-B2 | Piperazine carbamates and methods of making and using same | ABHD6, RABL6, ABHD16A | MGLL 46/4885ABHD6 1/4885PLA2G7 204/4885 |
| US-20190202801-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABHD6, RABL6, ABHD16A | MGLL 46/4885ABHD6 1/4885PLA2G7 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.